HeyJaredFrank Vinluan
STORY ANGLES - Focus on Strategic Acquisitions: Consistently highlights high-value acquisitions and their potential to reshape markets or pipelines.
- Indexed articles, last 90 days
- 17
- Latest publication
- Aug 13, 2026
- Outlet visibility, for MedCity News
- Top 5M sites
- Earliest in this view
- Jul 5, 2026
Latest articles
PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy - MedCity News (opens the original)
Read excerpt
PTC Therapeutics is expanding its prospects in rare disease, winning a bankruptcy auction for a Sangamo Therapeutics gene therapy that’s already on a fast path to regulatory review by the FDA. The PTC bid amounts to $111 million up front, the companies announced after Wednesday’s market close. Warren, New Jersey-based PTC is responsible for up to $100 million more in milestone payments tied to the regulatory progress of the therapy, isaralgagene civaparvovec (code name ST-920). A rolling FDA sub
Latigo Bio’s IPO Lands $346M for Pipeline of Non-Opioid Pain Drugs - MedCity News (opens the original)
Read excerpt
The race for non-opioid pain drugs continues, and Latigo Biotherapeutics is building the case for a molecule it says could offer advantages over the Vertex Pharmaceuticals product that was first in a new class of medicines. With Latigo’s pill on track to enter Phase 3 testing, the company secured $346 million in IPO cash to support this program and the rest of its pipeline. Research in non-opioid pain drugs has turned to sodium channels, pathways that transmit signals through the nervous system.
Moderna Gets FDA Approval for mRNA Flu Vaccine, But CDC Input Still Uncertain - MedCity News (opens the original)
Read excerpt
As the flu season unfolded last year, the available vaccines turned out to be mismatched to the strain that became dominant. The vaccines still offered some protection, but that protection was diminished. A Moderna flu vaccine made with technology that enables quick adjustments to respond to viral mutations now has FDA approval, and the company will make this shot available for the upcoming respiratory virus season. The regulatory approval announced late Wednesday covers adults age 50 and older.
Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company - MedCity News (opens the original)
Read excerpt
Supernus Pharmaceuticals and Indivior Pharmaceuticals, companies that built businesses in different areas of neuroscience, have reached a deal to combine into an entity with a broader portfolio of products and the financial flexibility to pursue additional avenues for growth. The agreement announced Monday is an all-stock deal that the companies describe as a merger of equals. The combined entity will be named Supernus, Inc., trading on the Nasdaq under the stock symbol “SUPN,” which is Supernus
Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company (opens the original)
Read excerpt
M&A activity is going beyond big pharma acquisitions with Supernus Pharmaceuticals and Indivior Pharmaceuticals reaching a stock deal that the companies call a merger of equals. The combined company’s portfolio will have 11 commercialized products in addiction, attention-deficit hyperactivity disorder, depression,
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For MedCity News, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.